Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer. The company's product portfolio also includes KOS-1584, an epothilone anticancer product candidate evaluated in dose-escalating Phase I clinical trial in patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist that is in Phase I clinical testing for the treatment of GERD. In addition, Kosan Biosciences develops KOS-2464, a preclinical stage product for cancer. The company was founded in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Co.

Research Grants 49 show all


$1.9M
2001

$1.8M
2002

$1.5M
2003

$2M
2004

$1.7M
2005

Patents 630show all

  • 224
    C12N - Microorganisms or enzymes
  • 201
    C07D - Heterocyclic compounds
  • 183
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 111
    C07H - Sugars
  • 103
    A61K - Preparations for medical, dental, or toilet purposes
  • 51
    C07K - Peptides
  • 40
    Y02P - Climate change mitigation technologies in the production or processing of goods
  • 27
    C40B - Combinatorial chemistry
  • 26
    C12R - Processes using microorganisms
  • 13
    A01K - Animal husbandry

Clinical Trials 3show all

3N/A

SEC Filings show all


65
8-K

23
10-Q

7
10-K

1
D

1
S-1

Contact Information

3832 Bay Center Place
Hayward, CA 94545
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$3,000,00051-1002006-07-19Acquired

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2006-07-19$3,000,000Series UnknownKingsbridge Capital

SEC Form D Funding Events

DateOfferedSoldType
2006-08-03Unknown Unknown Other (Paper Filing)